Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.

Item
http://www.wikidata.org/entity/Q37501529
New pharmacological strategies in rheumatic diseasesCan Synovial Pathobiology Integrate with Current Clinical and Imaging Prediction Models to Achieve Personalized Health Care in Rheumatoid Arthritis?Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countriesDecreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study.Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritisBody mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance.Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective studySwitching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry.Co-stimulation Therapy in Rheumatoid Arthritis: Today and Tomorrow.Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).
P2860

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.

Item
http://www.wikidata.org/entity/Q37501529
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Real-world effectiveness of ab ...... nal, prospective ACTION study.
@en
Real-world effectiveness of ab ...... nal, prospective ACTION study.
@nl
type
label
Real-world effectiveness of ab ...... nal, prospective ACTION study.
@en
Real-world effectiveness of ab ...... nal, prospective ACTION study.
@nl
prefLabel
Real-world effectiveness of ab ...... nal, prospective ACTION study.
@en
Real-world effectiveness of ab ...... nal, prospective ACTION study.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P932
P356
P1433
P1476
Real-world effectiveness of ab ...... nal, prospective ACTION study.
@en
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P932